Related Experiment Video
Updated: Oct 29, 2025

06:48
Author Spotlight: Evaluation of Protein-Condensate Dynamics in Live Human Cells
Published on: January 5, 2024
4.5K
Diverse Aggregation Kinetics Predicted by a Coarse-Grained Peptide Model.
Beata Szała-Mendyk1, Andrzej Molski1
1Faculty of Chemistry, Adam Mickiewicz University in Poznań, Umultowska 89b, 61-614 Poznań, Poland.
The Journal of Physical Chemistry. B
|July 12, 2021
Summary
Peptide aggregation kinetics are controlled by interchain attraction and chain stiffness. These factors influence aggregation modes, including nucleated and downhill pathways, and are affected by concentration and peptide length.
Area of Science:
- Biophysics
- Computational Chemistry
- Materials Science
Background:
- Protein and peptide aggregation are critical in medicine and industry.
- Understanding aggregate nucleation and growth mechanisms is essential.
- Experimental studies show diverse aggregation kinetics, including sigmoidal and downhill patterns.
Purpose of the Study:
- To investigate the molecular mechanisms governing peptide aggregation kinetics.
- To explore how interchain attraction and intrachain bending stiffness control aggregation.
- To model and reproduce experimentally observed aggregation modes.
Main Methods:
- Utilized a coarse-grained implicit solvent model for peptide aggregation simulations.
- Systematically varied parameters like interaction strength, stiffness, monomer concentration, and chain length.
- Analyzed simulation data to identify aggregation modes and transient morphologies.
Main Results:
- Interchain attraction strength is the primary determinant of aggregation mode (no aggregation, nucleated, or downhill).
- Chain stiffness modulates aggregation rates and the order of transient aggregates.
- Decreasing monomer concentration shifts aggregation from downhill to nucleated and no-aggregation.
- Longer peptide chains exhibit increased aggregation propensity.
Conclusions:
- The interplay of attraction and stiffness governs peptide aggregation pathways.
- Simulation results align with experimental observations on concentration-dependent and chain-length-dependent aggregation.
- The model provides insights into controlling peptide aggregation for various applications.
Related Concept Videos
Physiological Pharmacokinetic Models: Assumption with Protein Binding
115
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
115
Cooperative Allosteric Transitions
8.3K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.3K
Protein-Drug Binding: Mechanism and Kinetics
1.3K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.3K

